Trial Profile
A Phase Ib Study Evaluating the Safety and Tolerability of Durvalumab (MEDI4736) (Anti-PDL1) in Combination With Eribulin in Patients With HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Eribulin (Primary)
- Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer; Male breast cancer; Ovarian cancer
- Focus Adverse reactions
- 04 Aug 2020 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 24 May 2019 Planned primary completion date changed from 1 May 2019 to 1 May 2020.